Arnatar Therapeutics

Arnatar Therapeutics, headquartered in San Diego, is at the forefront of biotechnological innovation, harnessing the power of RNA biology to design personalized medicines. The company specializes in antisense drug discovery, a technique that involves creating molecules known as antisense oligonucleotides (ASOs) to target and modulate the expression of specific genes responsible for disease. This approach not only offers the potential for treating diseases at their genetic roots but also enables the development of highly personalized medical interventions.

The company's mission is driven by a dedication to meeting the urgent needs of patients suffering from both prevalent and rare diseases. Arnatar's antisense technology targets the RNA molecules involved in disease processes, either reducing or increasing their expression to achieve therapeutic effects. The company has already seen the success and recent approval of over ten antisense drugs, heralding a new era for RNA-targeted therapies.

Arnatar's core competencies include proprietary technologies and expertise in modulating disease-causing RNAs, a deep understanding of the biology and genetics of various diseases, and a proven track record in all phases of drug development—from target selection and lead identification through to clinical trials and regulatory approvals. Their team comprises experienced scientists with diverse expertise across drug development, RNA biology, and chemistry, emphasizing their capability to bring novel molecules to the market as either best-in-class or first-in-class RNA therapies.